Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Section Content Menu Skip to Common Links
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

About FDA

  • Print
  • Share
  • E-mail
-

NCTR Research Highlights

Red envelope icon for GovdeliveryGet e-mail updates when this information changes.

 

2013 Global Summit on Regulatory Science (GSRS13)

Topic:  Nanotechnology

Dates: September 11-12, 2013

Location:  Little Rock, Arkansas

REQUEST INFORMATION

Current Highlight from May 17, 2013

KRAS Mutant Subpopulations and Implications for Cancer Therapeutics

NCTR scientists published an invited review in Discovery Medicine (2013, 15:259-267) that discusses the implications of KRAS mutant subpopulations in colon tumors on the efficacy of personalized cancer treatments.  The authors summarize evidence that most colon tumors carry KRAS mutations; and few, if any, colon tumors are truly KRAS wild-type.  The use of monotherapies that target KRAS wild-type tumor cells creates an opportunity for the outgrowth of KRAS mutant subpopulations, which can lead to acquired resistance to treatment and relapse.  Thus, combination therapeutics that target KRAS mutant cells may provide a more effective treatment of advanced colorectal cancer. 

For additional information, please contact Barbara Parsons, Ph.D., Division of Genetic and Molecular Toxicology, FDA/NCTR, or Meagan Myers, Ph.D., Staff Fellow, Division of Genetic and Molecular Toxicology, FDA/NCTR.

-
-
 

Contact FDA

870-543-7000
National Center for Toxicological Research

Food and Drug Administration

3900 NCTR Road

Jefferson, AR 72079
-
-